Please note: the information on this page is provided for informational purposes only. As of 2011, Simmons Hanly Conroy is no longer accepting cases involving Celebrex.
Celebrex is a medication used to treat acute pain. It is manufactured by the company known as Pfizer and is part of a family of Cox-2 Inhibitors, which arrived on the pharmaceutical market in the late 1990s. Cox-2 Inhibitors reduce hormones to block pain and are prescribed to treat osteoarthritis, acute pain and painful menstrual cycles.
Celebrex currently carries the highest FDA warning related to serious or deadly risks of cardiovascular events and stomach ulcers. This drug remains on the market, although its cousins, Bextra and Vioxx, have been recalled.
Health Complications and Celebrex Lawsuits
Side effects and health complications linked to use of Celebrex vary from moderate to very serious. They include:
- Upset stomach/nausea
- Sore throat
- Heart attack
- Stomach ulcers
- Serious skin reactions
- Intestinal problems
On April 7, 2005, FDA Alert details information pertaining to the FDA request that packaging of Celebrex and other NSAIDS include a boxed warning. The warning is meant to note the serious risks of heart attack, stroke or other cardiovascular events that may cause risk of life-threatening gastrointestinal bleeding or death.
Simmons Hanly Conroy no longer accepts Celebrex lawsuit cases. Learn more about past litigation areas of the pharmaceutical lawyers at the firm or explore more information on our current areas of litigation. Please contact us with any questions.
Many of our pharmaceutical attorneys have national leadership experience with Celebrex lawsuits. In 2006, Shareholder Paul Hanly was court-appointed to three positions: as a member of the Plaintiffs’ Coordinating Committee in the coordinated New York State Bextra and Celebrex Products Liability Litigation, as liaison counsel between those proceedings and their federal multidistrict litigation (“MDL”) counterpart, and as a member of the MDL Plaintiffs’ Steering Committee. Also in 2006, Shareholder Jayne Conroy was selected to serve leading roles on the Discovery and Science Committees in those two litigations. Shareholder Clint Fisher was added to the Discovery Committee in 2007. Shareholder Mitchell Breit served on the New York State Court Liaison Counsel in Bextra and Celebrex Marketing, Sales Practices and Products Liability Litigation. Shareholder Trent Miracle also has federal leadership experience with Bextra and Celebrex litigation.
I am very pleased and had a wonderful experience with the firm. Would definitely use their services again.